Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2024
0mins
Source: Benzinga
- 临床试验结果显示：哮喘治疗中的快速进展：临床试验结果显示，哮喘治疗中的快速进展，为广泛性焦虑障碍（GAD）患者带来潜在益处。
- 教育机构推动：开源学习框架提升心理治疗标准：Beckley Academy发布首个开源学习框架，旨在推动心理治疗标准，填补行业培训标准和认证的缺失。
- 生物科技公司签署协议：开发新型神经可塑性药物：Enveric Biosciences与另一生物技术公司签署三项非约束性协议，以外部许可方式开发治疗抑郁症、焦虑症和成瘾障碍的新型小分子药物。
- **心理治疗领域取得突破：抑
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.60 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.740
Low
19.00
Averages
28.60
High
35.00
Current: 16.740
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
